Primary dysmenorrhea : Advances in pathogenesis and management

Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Obstetrics and gynecology (New York. 1953) 2006-08, Vol.108 (2), p.428-441
1. Verfasser: YUSOFF DAWOOD, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 441
container_issue 2
container_start_page 428
container_title Obstetrics and gynecology (New York. 1953)
container_volume 108
creator YUSOFF DAWOOD, M
description Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.
doi_str_mv 10.1097/01.AOG.0000230214.26638.0c
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68697344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68697344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRbK3-BQmC3hJnP5psPAilaBUK9aDgbdnsTtpIPupuKvTfu9pA5zKHed4Z5iHkhkJCIc_ugSaz1SKBUIwDoyJhacplAuaEjKnMeMw4_zwl4zDP40wKMSIX3n8FnqY5PycjmkoJnGZj8vjmqka7fWT3vsG2c26DOnqIZvZHtwZ9VLXRVvebbo0t-spHurVRo1u9xoD3l-Ss1LXHq6FPyMfz0_v8JV6uFq_z2TI2PGN9nIM2FmUxRWZTygALzSxwLplJKWgUheTUSgNmSm1uQRpRCoMit0WWQzblE3J32Lt13fcOfa-ayhusa91it_MqlWmecSEC-HAAjeu8d1iq7eFBRUH92VNAVbCnjvbUvz0FJoSvhyu7okF7jA66AnA7ANobXZcuOKr8kZPBMA-KfwFcbnhp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68697344</pqid></control><display><type>article</type><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>YUSOFF DAWOOD, M</creator><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><description>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1097/01.AOG.0000230214.26638.0c</identifier><identifier>PMID: 16880317</identifier><identifier>CODEN: OBGNAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage ; Biological and medical sciences ; Contraceptives, Oral, Combined - administration &amp; dosage ; Decision Trees ; Dysmenorrhea - diagnosis ; Dysmenorrhea - drug therapy ; Dysmenorrhea - physiopathology ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Ibuprofen - administration &amp; dosage ; Ketoprofen - administration &amp; dosage ; Medical sciences ; Naproxen - administration &amp; dosage ; Non tumoral diseases</subject><ispartof>Obstetrics and gynecology (New York. 1953), 2006-08, Vol.108 (2), p.428-441</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</citedby><cites>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18001369$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16880317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Contraceptives, Oral, Combined - administration &amp; dosage</subject><subject>Decision Trees</subject><subject>Dysmenorrhea - diagnosis</subject><subject>Dysmenorrhea - drug therapy</subject><subject>Dysmenorrhea - physiopathology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Ibuprofen - administration &amp; dosage</subject><subject>Ketoprofen - administration &amp; dosage</subject><subject>Medical sciences</subject><subject>Naproxen - administration &amp; dosage</subject><subject>Non tumoral diseases</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhhdRbK3-BQmC3hJnP5psPAilaBUK9aDgbdnsTtpIPupuKvTfu9pA5zKHed4Z5iHkhkJCIc_ugSaz1SKBUIwDoyJhacplAuaEjKnMeMw4_zwl4zDP40wKMSIX3n8FnqY5PycjmkoJnGZj8vjmqka7fWT3vsG2c26DOnqIZvZHtwZ9VLXRVvebbo0t-spHurVRo1u9xoD3l-Ss1LXHq6FPyMfz0_v8JV6uFq_z2TI2PGN9nIM2FmUxRWZTygALzSxwLplJKWgUheTUSgNmSm1uQRpRCoMit0WWQzblE3J32Lt13fcOfa-ayhusa91it_MqlWmecSEC-HAAjeu8d1iq7eFBRUH92VNAVbCnjvbUvz0FJoSvhyu7okF7jA66AnA7ANobXZcuOKr8kZPBMA-KfwFcbnhp</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>YUSOFF DAWOOD, M</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><author>YUSOFF DAWOOD, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Contraceptives, Oral, Combined - administration &amp; dosage</topic><topic>Decision Trees</topic><topic>Dysmenorrhea - diagnosis</topic><topic>Dysmenorrhea - drug therapy</topic><topic>Dysmenorrhea - physiopathology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Ibuprofen - administration &amp; dosage</topic><topic>Ketoprofen - administration &amp; dosage</topic><topic>Medical sciences</topic><topic>Naproxen - administration &amp; dosage</topic><topic>Non tumoral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YUSOFF DAWOOD, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary dysmenorrhea : Advances in pathogenesis and management</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>108</volume><issue>2</issue><spage>428</spage><epage>441</epage><pages>428-441</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><coden>OBGNAS</coden><abstract>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>16880317</pmid><doi>10.1097/01.AOG.0000230214.26638.0c</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0029-7844
ispartof Obstetrics and gynecology (New York. 1953), 2006-08, Vol.108 (2), p.428-441
issn 0029-7844
1873-233X
language eng
recordid cdi_proquest_miscellaneous_68697344
source MEDLINE; Journals@Ovid Complete
subjects Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Biological and medical sciences
Contraceptives, Oral, Combined - administration & dosage
Decision Trees
Dysmenorrhea - diagnosis
Dysmenorrhea - drug therapy
Dysmenorrhea - physiopathology
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Ibuprofen - administration & dosage
Ketoprofen - administration & dosage
Medical sciences
Naproxen - administration & dosage
Non tumoral diseases
title Primary dysmenorrhea : Advances in pathogenesis and management
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A48%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20dysmenorrhea%20:%20Advances%20in%20pathogenesis%20and%20management&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=YUSOFF%20DAWOOD,%20M&rft.date=2006-08-01&rft.volume=108&rft.issue=2&rft.spage=428&rft.epage=441&rft.pages=428-441&rft.issn=0029-7844&rft.eissn=1873-233X&rft.coden=OBGNAS&rft_id=info:doi/10.1097/01.AOG.0000230214.26638.0c&rft_dat=%3Cproquest_cross%3E68697344%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68697344&rft_id=info:pmid/16880317&rfr_iscdi=true